Introduction {#section6-2050312120946521}
============

Hypertension is a significant contributor to the global burden of disease and mortality.^[@bibr1-2050312120946521]^ An estimated 1.13 billion (14.7%) people worldwide have hypertension^[@bibr2-2050312120946521]^ and the proportion is estimated to rise to over 29% by 2025.^[@bibr3-2050312120946521]^ Hypertension prevalence was reported highest in Africa (30%) in 2014 and ranged from 25% to 41% in sub-Saharan Africa.^[@bibr4-2050312120946521]^ The consequences of poor blood pressure (BP) control are known to cause human suffering and impose severe financial and service burdens on health systems.^[@bibr1-2050312120946521],[@bibr5-2050312120946521],[@bibr6-2050312120946521]^ In Ethiopia, non-communicable diseases are estimated to account 30% of total annual deaths, of which 9% is attributed to cardiovascular diseases (CVD).^[@bibr4-2050312120946521]^ A 24% death rate from CVD was also reported in Addis Ababa.^[@bibr7-2050312120946521]^ The reported prevalence of hypertension in different regions of Ethiopia varied widely^[@bibr8-2050312120946521][@bibr9-2050312120946521][@bibr10-2050312120946521][@bibr11-2050312120946521]--[@bibr12-2050312120946521]^ and the prevalence in the country is estimated to be between 20% and 30%.^[@bibr13-2050312120946521],[@bibr14-2050312120946521]^

Hypertension management involves pharmacological and non-pharmacological interventions.^[@bibr6-2050312120946521],[@bibr15-2050312120946521]^ Despite hypertension being the major risk factor for CVD, it remains inadequately managed, and BP is often not adequately controlled in clinical practice.^[@bibr16-2050312120946521],[@bibr17-2050312120946521]^ This is pronounced in developing countries including Ethiopia. Most Ethiopian populations receive medical care in primary health care facilities. Health centers (HCs) are the main primary health care providing facilities in Addis Ababa, the capital of Ethiopia. HCs are staffed mainly with health officers and nurses for the provision of medical care, unlike hospitals where physicians take the primary role.^[@bibr18-2050312120946521]^ HCs provide outpatient services for patients with hypertension in Addis Ababa. Hypertension-related studies in Ethiopia are mainly focused on the prevalence and conducted in hospital setups. There is limited data on hypertension management at primary health care facilities. Therefore, this study had two objectives: (1) determine the level of BP control among hypertensive patients on medication(s); and (2) to identify potential determinants of uncontrolled BP at primary health care facilities in Addis Ababa, Ethiopia. Addis Ababa had an estimated population of four million in the year 2019, with an annual growth rate of 3.8%.^[@bibr19-2050312120946521]^ The city has 10 sub-cities. According to the Ethiopian health care tier, one HC serves 15,000--25,000 population.^[@bibr20-2050312120946521]^

Methods {#section7-2050312120946521}
=======

Study design {#section8-2050312120946521}
------------

An institution-based cross-sectional study was conducted in 12 HCs of Addis Ababa located in four sub-cities, namely, Gulelle, Lideta, Nifasilk-Lafto, and Akaki-Kaliti from 3 August to 30 October 2015.

Sample size and sampling technique {#section9-2050312120946521}
----------------------------------

The HCs were selected by multistage sampling technique considering the 10 sub-cities of Addis Ababa as geographical clusters and hence as a primary sampling unit. The HCs in the selected four sub-cities were considered as a secondary sampling unit. Simple random sampling was used to select the sub-cities and HCs.

The sample size was calculated using the formula of a single population proportion with a finite population correction as follows

$$n = \frac{Nz^{2}pq}{d^{2}\left( {N - 1} \right) + z^{2}pq}$$

To calculate the sample size, (*n*):1.96 was substituted for Z which is the standard normal value at 95% confidence level, *p* which is the proportion of controlled BP was taken as 50%, the value of *q* was taken as 1 − *p, d* which is the margin of error was taken as 0.05, and 1155 was substituted for *N* which was the number of hypertensive patients at the HCs. Finally, 2 for the design effect multiplied the sample size calculated according to the above formula, and an addition of 10% non-response brought the final sample size to 634. The sample size at each HC was allocated using probability proportional to the total number of hypertensive patients on medication at specific HC. Study participants from each HC were selected by systematic random sampling.

Ethics approval {#section10-2050312120946521}
---------------

Ethical clearance was obtained from the Ethics Review Committee of the School of Pharmacy, Addis Ababa University (ERB/SOP/53/04/2015), and Health Bureau Institutional Review Board of Addis Ababa City Administration (AAHB/7023/227). A support letter was obtained from the Health Bureau to the included sub-cities health offices. A support letter was written from the four sub-cities health offices to HCs residing in each sub-city. Permission was obtained from each HC medical director to conduct the study. The benefits and risks of the study were explained to each participant included in the study, and oral informed consent was obtained from each patient involved in the study. To ensure confidentiality, name and other identifiers of patients and health care professionals were not recorded on the data collection tools.

Data collection procedure {#section11-2050312120946521}
-------------------------

Participants were asked for their consent and verified for inclusion. The inclusion criteria for the study were hypertensive patients attending the outpatient departments of selected HCs with age of 18 years or above, on medication for hypertension at least for 6 months at the selected HC. Data were collected by patient interview and medical record review. A record review was done to obtain three BP readings from three consecutive visits. A data abstraction format was used to record data regarding comorbid condition/s, BP measurements, and type(s) of antihypertensive medication(s) from the patient's medical record. Patients were interviewed after the review of their medical record to obtain socio-demographic, disease, lifestyle, and drug-related information. Height, weight, and waist circumference were measured on the day of the interview (Supplemental material). The data were collected by a nurse. To ensure the quality of data, a pre-test was done on 5% of the total sample at one HC.

Data analysis {#section12-2050312120946521}
-------------

The data were analyzed using Statistical Package for the Social Sciences (SPSS) version 20.0. Descriptive statistics were used to summarize study variables and evaluate the distribution of responses. The level of BP control was assessed by using the average of three BP records obtained from three different visits. Logistic regression was used to identify potential determinant variables for the outcome measure (uncontrolled BP). A variable with p \< 0.25 in the bivariable analysis (presented as crude odds ratio (COR) at 95% CI) was included in multivariable logistic regression analysis (presented as adjusted odds ratio (AOR) at 95% confidence interval (CI)). A variable was considered to be significant for a p-value of less than 0.05 at 95% CI. Controlled BP was defined based on the joint national committee (JNC) 8 guideline^[@bibr21-2050312120946521]^ as BP \< 150/90 mmHg in hypertensive patients aged 60 or older, or BP \< 140/90 mmHg in hypertensive patients aged less than 60 years and all ages of hypertensive patients with diabetes or chronic kidney disease (CKD). Sensitivity analysis was done by using a cutoff point of BP \< 130/80 mmHg for those with diabetes and CKD and BP \< 140/90 mmHg for others. Body mass index was calculated as weight over height per meter square and classified as underweight (\<18.5 kg/m^2^), normal (18.5--24.9 kg/m^2^), overweight (25--29.9 kg/m^2^), and obese (⩾30 kg/m^2^). Central obesity was defined as waist circumference *\>*102cm for men and *\>*88 cm for women. A patient was described as physically active if he or she performs physical activity at least 30 min per day for at least 5 days per week. Persons who smoke at the time of data collection and who stopped smoking in less than a year were considered a current smoker.

Results {#section13-2050312120946521}
=======

Overall, 634 participants were included in this study with a response rate of 616 (97%). The number of participants per HC was as follows: Selam HC (149), Shegole HC (35), Shiro meda HC (34), Guto Meda HC (33), Lideta HC (109), Teklehaymanot HC (20), Wereda 03 HC (80), Wereda 09 HC (39), Wereda 06 HC (33), Wereda 12 HC (30), Kaliti HC (26), and Gelan HC (28). Most study participants were females 346 (56.2%). The mean age of the respondents was 58.9 (SD = 13.0) years and the majority 321 (52.1%) were with the age of 60 or above. Majority 419 (68.0%) were married, 213 (34.6%) had no formal education, and 200 (32.5%) were housewives. Of all the study participants, 368 (59.7%) had normal body weight and 196 (31.8%) were overweight. The measurement of waist circumference showed that 202 (58.4 %) of females and 53 (19.6 %) of male participants had abdominal obesity. Nearly one-third (n = 198) of patients had a family history of hypertension and 559 (90.7%) had a monthly follow-up at the HC. Only four (0.6%) measured their BP every day. Only one-fifth (n = 122) had comorbid illnesses, among which 98 (15.9%) were diabetic. There were no pregnant patients and patients with CKD. The mean duration of time (year) since the diagnosis of hypertension was 5.59 ± 5.77. The mean duration of drug therapy for hypertension was 4.6 (SD = 4.9) years with a range of 0.5--40. Two-third of the patients (n = 417) have been taking antihypertensive therapy for less than 5 years, and nearly half of them obtain their medications for free 294 (47.7%). Among the study participants, 209 (33.9%) reported the experience of at least one side effect from the medication/s ([Table 1](#table1-2050312120946521){ref-type="table"}).

###### 

Socio-demographic, anthropometric, and clinical characteristics of hypertensive patients attending health centers of Addis Ababa, 2015.

![](10.1177_2050312120946521-table1)

  Variable                                                         Frequency (%)
  ---------------------------------------------------------------- ---------------
  Sex                                                              
   Female                                                          346 (56.2)
   Male                                                            270 (43.8)
  Age                                                              
   \<60 years                                                      295 (47.9)
   ⩾60 years                                                       321 (52.1)
  Marital status                                                   
   Married                                                         419 (68.0)
   Widowed                                                         120 (19.5)
   Divorced                                                        46 (7.5)
   Single                                                          31 (5.0)
  Educational status                                               
   No formal education                                             213 (34.6)
   Primary education                                               209 (33.9)
   Secondary education                                             110 (17.9)
   College/university                                              84 (13.6)
  Work status                                                      
   House wife                                                      200 (32.5)
   Private business                                                144 (23.4)
   Retired                                                         123 (19.9)
   Government employee                                             95 (15.4)
   Unemployed                                                      33 (5.4)
   Others^[a](#table-fn2-2050312120946521){ref-type="table-fn"}^   21 (3.4)
  Body mass index                                                  
   Under weight                                                    14 (2.3)
   Normal weight                                                   368 (59.7)
   Over weight                                                     196 (31.8)
   Obese                                                           38 (6.2)
  Waist circumference                                              
   Female                                                          
    \<88 cm                                                        144 (41.6)
    ⩾88 cm                                                         202 (58.4)
   Male                                                            
    \<102 cm                                                       217 (80.4)
    ⩾102 cm                                                        53 (19.6)
  Family history of hypertension                                   
   Yes                                                             198 (32.1)
   No                                                              418 (67.9)
  Duration of hypertension diagnosis                               
   \<5 years                                                       368 (59.7)
   5--10 years                                                     141 (22.9)
   ⩾10 years                                                       107 (17.4)
  Frequency of follow-up                                           
   Weekly                                                          4 (0.6)
   Every 2 weeks                                                   33 (5.4)
   Monthly                                                         559 (90.8)
   Every 2 months                                                  16 (2.6)
   Others^[b](#table-fn3-2050312120946521){ref-type="table-fn"}^   4 (0.6)
  Frequency of BP measurement                                      
   Monthly                                                         304 (49.4)
   Weekly                                                          150 (24.4)
   Every 2 weeks                                                   135 (21.9)
   When feeling ill                                                16 (2.6)
   Every day                                                       4 (0.6)
   Others^[c](#table-fn4-2050312120946521){ref-type="table-fn"}^   7 (1.1)
  Comorbid conditions                                              
   Diabetes mellitus                                               98 (15.9)
   Asthma                                                          6 (1.0)
   CVD                                                             5 (0.8)
   HIV/AIDS                                                        3 (0.5)
   Others^[d](#table-fn5-2050312120946521){ref-type="table-fn"}^   10 (1.6)
  Duration of therapy                                              
   \<5 years                                                       417 (67.7)
   5--10 years                                                     125 (20.3)
   ⩾10 years                                                       74 (12)
  Source of medication/s                                           
   Free of charge                                                  294 (47.7)
   By sponsorship                                                  44 (7.2)
   Self-sponsored                                                  278 (45.1)
  Side effect                                                      
   Yes                                                             209 (33.9)
   No                                                              407 (66.1)
  Side effects                                                     
   Headache                                                        103 (16.7)
   Weakness                                                        92 (14.9)
   Dry mouth                                                       38 (6.2)
   Postural hypotension                                            37 (6.0)
   Gastrointestinal complaint                                      7 (1.1)
   Erectile dysfunction                                            5 (0.8)
   Others^[a](#table-fn2-2050312120946521){ref-type="table-fn"}^   21 (3.4)

BP: blood pressure; CVD: cardiovascular diseases; HIV: human immune virus; AIDS: acquired immune deficiency syndrome.

Daily laborer, farmer, construction, guard.

Every 3 months.

Twice weekly, every 2 months.

Musculoskeletal disease, gout, migraine.

Among the participants, very few (six) reported being a current smoker, and 75 participants reported the use of alcohol. Concerning physical exercise, 185 (30.0%) participants reported to perform a physical exercise among whom 88 (14.3%) were physically active. Above three-fourth of the participants reported reducing salt in their diet.

The overall utilization of antihypertensive drugs by pharmacologic category showed thiazide diuretics to be the most commonly prescribed 225 (36.5%) followed by angiotensin-converting enzyme inhibitors (ACEIs) 180 (29.2%) and calcium channel blockers (CCBs) 159 (25.8%). Nearly 80% of patients were on monotherapy (n = 486) and alpha two agonist (methyldopa) was the most common monotherapy medication used 128 (20.8 %). For multiple drug therapy, thiazide and ACEI were the most common combination drugs used 46 (7.5%). The treatment regimen of 523 (84.9%) patients was not modified at their latest visit. More than one-third of the study participants had a controlled systolic blood pressure (SBP), while half had controlled diastolic blood pressure (DBP). Based on JNC 8, the overall control of BP was achieved in one-third (n = 191) of the study participants ([Table 2](#table2-2050312120946521){ref-type="table"}). In our sensitivity analysis, the level of BP control was only 19% (n = 117) when target BP for diabetic and/or patients with CKD s was BP \< 130/80 mmHg and \<140/90 for the remaining patients. On the other hand, when a cutoff point of \<140/90 mmHg was used for all the study participants, only 24% (n = 148) of patients had controlled BP.

###### 

Drug therapy, treatment modification, and blood pressure control among hypertensive patients attending health centers of Addis Ababa, 2015.

![](10.1177_2050312120946521-table2)

  Drugs                                          Frequency (%)
  ---------------------------------------------- ---------------
  Monotherapy                                    485 (78.7)
   Methyldopa                                    128 (20.8)
   Enalapril                                     123 (20.0)
   Hydrochlorthiazide                            108 (17.5)
   Nifedepine                                    108 (17.5)
   Amlodipine                                    1 (0.2)
   Atenolol                                      13 (2.1)
   Propranolol                                   4 (0.6)
  Two drugs combinations                         125 (20.3)
   Hydrochlorthiazide + Enalapril                45 (7.3)
   Hydrochlorthiazide + Nifedepine               42 (6.8)
   Hydrochlorthiazide + Atenolol                 13 (2.1)
   Hydrochlorthiazide + Propranolol              3 (0.5)
   Hydrochlorthiazide + Methyldopa               9 (1.5)
   Enalapril + Nifedepine                        1 (0.2)
   Enalapril + Atenolol                          1 (0.2)
   Enalapril + Propranolol                       2 (0.3)
   Enalapril + Methyldopa                        2 (0.3)
   Nifedepine + Methyldopa                       3 (0.5)
   Atenolol + Methyldopa                         1 (0.2)
   Atenolol + Amlodipine                         3 (0.5)
  Three drugs combinations                       6 (1.0)
   Hydrochlorthiazide + Enalapril + Atenolol     4 (0.6)
   Enalapril + Nifedepine + Atenolol             1 (0.2)
   Hydrochlorthiazide + Enalapril + Methyldopa   1 (0.2)
  Treatment modification                         
   No modification                               523 (84.9)
   Switch to another drug                        62 (10.1)
   Addition of drug                              19 (3.1)
   Increase in dose                              3 (0.5)
   Decrease in dose                              1 (0.2)
   Deletion of drug                              2 (0.3)
   Increase in frequency                         1 (0.2)
   Decrease in frequency                         5 (0.8)
  Control of BP                                  
   Uncontrolled SBP                              359 (58.3)
   Uncontrolled DBP                              297 (48.2)
   Uncontrolled BP                               425 (69)

BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.

In multivariable logistic regression analysis, significant determinants for having uncontrolled BP were age \< 60 years (AOR = 3.06, 95% CI: 1.96, 4.78, p \< 0.001) compared with those with age ⩾ 60 years and duration of hypertension diagnosis of 10 years or longer (AOR = 1.96, 95% CI: 1.11, 3.43, P = 0.02) compared with those with a diagnosis of less than 5 years. On the other hand, tertiary-level education (AOR = 0.26, 95% CI: 0.13, 0.54, p \< 0.001) compared with those with no formal education and weekly BP measurement (AOR = 0.57, 95% CI: 0.36, 0.90, p = 0.02) compared with monthly measurement were found to be predictors to achieve controlled BP ([Table 3](#table3-2050312120946521){ref-type="table"}).

###### 

Determinants of uncontrolled BP among hypertensive patients attending health centers of Addis Ababa, 2015.

![](10.1177_2050312120946521-table3)

  Variable                      Blood pressure control   COR (95% CI)   AOR (95% CI)                                                               
  ----------------------------- ------------------------ -------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------
  Age category                                                                                                                                     
   ⩾60 years                    191 (31.0)               130 (21.1)     1.00                                                                       1.00
   \<60 years                   234 (38.0)               61 (9.9)       2.61 (1.82, 3.74)                                                          3.06 (1.96, 4.78)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^
  Marital status                                                                                                                                   
   Married                      297 (48.2)               122 (19.8)     1.00                                                                       1.00
   Single                       24 (3.9)                 7 (1.1)        1.41 (0.59, 3.36)                                                          1.56 (0.59, 4.12)
   Divorced                     31 (5.0)                 15 (2.4)       0.85 (0.44, 1.63)                                                          0.93 (0.45, 1.93)
   Widowed                      73 (11.9)                47 (7.6)       0.64 (0.42, 0.98)                                                          0.75 (0.45, 1.24)
  Education level                                                                                                                                  
   No formal education          143 (23.2)               70 (11.4)      1.00                                                                       1.00
   Primary education            149 (24.2)               60 (9.7)       1.22 (0.80,1.84)                                                           0.82 (0.51, 1.32)
   Secondary education          83 (13.5)                27 (4.4)       1.51 (0.89,2.53)                                                           0.70 (0.36, 1.35)
   College/university           50 (8.1)                 34 (5.5)       0.72 (0.43, 1.21)                                                          0.26 (0.13, 0.54)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^
  Frequency of BP measurement                                                                                                                      
   Monthly                      220 (35.7)               84 (13.6)      1.00                                                                       1.00
   Every day                    2 (0.3)                  2 (0.3)        0.38 (0.05, 2.75)                                                          0.56 (0.06, 5.01)
   Weekly                       87 (14.1)                63 (10.2)      0.53 (0.35, 0.79)                                                          0.57 (0.36, 0.90)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^
   Every 2 weeks                99 (16.1)                36 (5.8)       1.05 (0.67, 1.66)                                                          1.13 (0.69, 1.86)
   When feeling ill             13 (2.1)                 3 (0.5)        1.66 (0.46, 5.95)                                                          1.34 (0.35, 5.14)
   Others                       4 (0.6)                  3 (0.5)        0.51 (0.11, 2.32)                                                          0.41 (0.08, 2.06)
  Work status                                                                                                                                      
   House wife                   124 (20.1)               76 (12.3)      1.00                                                                       1.00
   Private business             110 (17.9)               34 (5.5)       1.98 (1.23, 3.20)                                                          2.09 (1.17, 3.74)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^
   Retired                      83 (13.5)                40 (6.5)       1.27 (0.79, 2.04)                                                          1.79 (1.01, 3.18)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^
   Government employee          73 (11.9)                22 (3.6)       2.03 (1.17, 3.55)                                                          2.41 (1.18, 4.90)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^
   Unemployed                   24 (3.9)                 9 (1.5)        1.63 (0.72, 3.70)                                                          1.81 (0.75, 4.41)
   Others                       11 (1.8)                 10 (1.6)       0.67 (0.27, 1.66)                                                          0.70 (0.26, 1.90)
  Duration of diagnosis                                                                                                                            
   \<5 years                    249 (40.4)               119 (19.3)     1.00                                                                       1.00
   5--10 years                  94 (15.3)                47 (7.6)       0.96 (0.63, 1.44)                                                          1.06 (0.65, 1.71)
   ⩾10 years                    82 (13.3)                25 (4.1)       1.57 (0.95, 2.58)                                                          1.96 (1.11, 3.43)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^
  Source of medication/s                                                                                                                           
   Free of charge               194 (31.5)               100 (16.2)     1.00                                                                       1.00
   By sponsorship               27 (4.4)                 17 (2.8)       0.82 (0.43, 1.57)                                                          0.96 (0.45, 2.05)
   Self-sponsored               204 (33.1)               74 (12.0)      1.42 (0.99, 2.04)                                                          1.35 (0.88, 2.06)
  Drug group                                                                                                                                       
   Thiazides                    70 (11.4)                38 (6.2)       1.00                                                                       1.00
   ACEI                         87 (14.1)                36 (5.8)       1.31 (0.75, 2.28)                                                          1.20 (0.66, 2.20)
   CCB                          72 (11.7)                37 (6.0)       1.06 (0.60, 1.85)                                                          1.07 (0.58, 1.96)
   β-blockers                   7 (1.1)                  10 (1.6)       0.38 (0.13, 1.08)                                                          0.35 (0.11, 1.13)
   Alpha 2 agonist              100 (16.2)               28 (4.5)       1.94 (1.09, 3.45)^[a](#table-fn8-2050312120946521){ref-type="table-fn"}^   1.78 (0.94, 3.39)
   Thiazide + ACEI              35 (5.7)                 11 (1.8)       1.73 (0.79, 3.78)                                                          1.52 (0.65, 3.56)
   Thiazide + CCB               24 (3.9)                 18 (2.9)       0.72 (0.35, 1.49)                                                          0.85 (0.38, 1.91)
   Thiazide + β-blockers        10 (1.6)                 6 (1.0)        0.91 (0.31, 2.68)                                                          0.81 (0.25, 2.57)
   Other combination            20 (3.2)                 7 (1.1)        1.55 (0.60, 3.99)                                                          0.52, 4.10)

BP: blood pressure; COR: crude odds ratio; CI: confidence interval; AOR: adjusted odds ratio; ACEI: angiotensin-converting enzyme inhibitor; CCB: calcium channel blocker.

Statistically significant.

Discussions {#section14-2050312120946521}
===========

The result of the study showed that only one-third of hypertensive patients on pharmacologic treatment had a controlled BP (31%). Inadequate control of BP appears to be a prevalent problem challenging the primary care in Addis Ababa. The level of BP control found in this study (31%) is lower than obtained from HC-based studies from Chile (59.7%),^[@bibr22-2050312120946521]^ Oman (39%),^[@bibr23-2050312120946521]^ Greece (55.6%),^[@bibr24-2050312120946521]^ the United States (49.8 %),^[@bibr25-2050312120946521]^ and South Africa (57%).^[@bibr26-2050312120946521]^ This difference in the level of BP control might be due to a more goal-oriented strategy in the treatment of hypertension, as the use of combination antihypertensive agents was common in most of the studies. In addition, the difference in the expertise of health professionals involved in the management of hypertension might have contributed to the discrepancy. Moreover, in three of the studies, hypertensive patients on lifestyle modifications who were not on antihypertensive drugs were included^[@bibr22-2050312120946521],[@bibr25-2050312120946521],[@bibr27-2050312120946521]^ which could have contributed to better control of BP than our study.

The level of BP control in this study was similar to the result obtained from hospital-based studies conducted in Zimbabwe (32.8 %),^[@bibr28-2050312120946521]^ Kenya (33.4%),^[@bibr29-2050312120946521]^ and Nigeria (35.0%).^[@bibr30-2050312120946521]^ This similarity in the level of BP control might be a result of the similarity in the inclusion criteria of the studies as only hypertensive patients on pharmacologic therapy were included in the studies similar to the present study. On the contrary, a study conducted in the United States at a different level of the health system showed 60% of treated hypertensive people to have a controlled BP^[@bibr31-2050312120946521]^ and hospital-based studies from Adama, Ethiopia, and Nigeria showed a BP control level of 43.6%^[@bibr32-2050312120946521]^ and 42%,^[@bibr33-2050312120946521]^ respectively. This difference in level of BP control might have resulted from the frequent use of combination antihypertensive therapy in hospitals as patients attending hospitals have associated comorbidities.

The proportion of patients with controlled SBP and DBP was almost similar from a study in Saudi Arabia (40.4% and 51.6%)^[@bibr34-2050312120946521]^ but lower than a study in the United States (55.7% and 77.1%).^[@bibr27-2050312120946521]^ This difference in the level of control of SBP and DBP might be due to age-related increase in SBP as a large proportion of study participants (52.1%) were older than 60 years of age.^[@bibr35-2050312120946521],[@bibr36-2050312120946521]^ More importantly, the level of health care in the United States is expected to be better than in Ethiopia in terms of resources and human skill.

In the study, age younger than 60 years was a contributing factor for poor BP control. A similar result was obtained from a study in Brazil.^[@bibr37-2050312120946521]^ On the other hand, the result of other studies showed that patients aged younger than 60 years were more likely to have controlled BP than older patients.^[@bibr27-2050312120946521],[@bibr29-2050312120946521]^ Better BP control among the elderly in this study may be because of an increased prevalence of comorbidities hence a high probability of intensive treatment and/or a better rate of adherence. In addition, health professionals could have shown more concern in counseling and ordering appropriate management for elders.

Consistent with our findings, a study in Chile at HC set up showed a low education level to have a negative association with BP control.^[@bibr22-2050312120946521]^ This is most likely associated with the level of awareness of hypertension and adherence to lifestyle modifications to decrease BP. In addition, government employees, retirees, and patients on private businesses were more likely to have uncontrolled BP than housewives. This might have resulted because of forgetfulness and hence non-adherence to antihypertensive medications.

In our study, being hypertensive for a longer period (⩾10 years) was found to be a significant predictor for not achieving target BP. This could be due to asymptomatic nature of the disease, a decrease in health-seeking behavior from patients and clinical inertia.^[@bibr38-2050312120946521]^

More frequent BP monitoring is one of the essential factors to achieve target BP.^[@bibr6-2050312120946521],[@bibr16-2050312120946521]^ We found weekly BP measurement to be a significant predictor to have controlled BP. Encouraging home-based BP measurement is one of the ideal interventions that may increase patients' health-seeking behavior, adjustment of lifestyle, and adherence to their medication.

The antihypertensive medication utilization pattern in this study was more similar to a study conducted in South Africa.^[@bibr26-2050312120946521]^ However, a study conducted in Chile^[@bibr20-2050312120946521]^ and the United States^[@bibr25-2050312120946521]^ used ACEI more often than diuretics. This frequent use of ACEI over diuretic might be a result of a large proportion of diabetic and CKD patients included in Chile and US studies. An additional factor that might have contributed to this discrepancy is race.^[@bibr6-2050312120946521],[@bibr21-2050312120946521]^ The frequent use of methyldopa in this study might have resulted from gaps in knowledge among health professionals involved in the management of hypertension in the HCs, lack of other optional drugs or lack of standard treatment guideline to control prescribing practice at the HCs.

Most (80%) of our study participants were prescribed a single antihypertensive agent. This was similar to a study conducted in Zimbabwe (70%).^[@bibr28-2050312120946521]^ However, different results were reported on studies from Chile (34%)^[@bibr22-2050312120946521]^ and the United States (29%).^[@bibr27-2050312120946521]^ The high prevalence of antihypertensive monotherapy in the presence of uncontrolled BP should be a concern. To achieve optimal BP level, the use of multiple antihypertensive agents is recommended.^[@bibr6-2050312120946521],[@bibr15-2050312120946521][@bibr16-2050312120946521]--[@bibr17-2050312120946521],[@bibr21-2050312120946521],[@bibr39-2050312120946521]^ A study also showed the benefit of using multiple antihypertensive agents to achieve optimal BP control.^[@bibr22-2050312120946521]^ The prevalent use of monotherapy might have resulted from a lack of drug availability at the health facilities and unaffordability of drugs by patients.^[@bibr28-2050312120946521]^

Switching to another drug and the addition of a drug were the leading type of treatment modifications. This might be because most of the present study participants had uncontrolled BP.^[@bibr40-2050312120946521]^ The treatment modification was low when compared with a study by Banegas et al.,^[@bibr41-2050312120946521]^ which reported treatment modification in 49% of hypertensive patients from which the addition of a drug and increasing dose were observed more frequently. This discrepancy might be a result of the frequent use of combination antihypertensive therapy for hypertension in the later study and clinical inertia in the present study.

Almost all patients did not smoke, which might be a result of the Ethiopian socio-cultural influence. More than one-third of the study participants were overweight or obese and one-fifth of the female, as well as two-third of the male participants had abdominal obesity. This result is different from the result of the study by Tesfaye and Wall^[@bibr8-2050312120946521]^ conducted in Addis Ababa which showed 20% of males and 38% of females to have a BMI of ⩾25 kg/m^2^ and 12.9% of males and 64.6% of females to have abdominal obesity. This difference might be a result of the difference in the age of the participants; predominance of elderly patients in the present study; the difference in the characteristics of the study population; inclusion of patients without a diagnosis of hypertension in the latter study; or a change in the lifestyle of the population of Addis Ababa. Since high BMI and increased abdominal circumference are risk factors for hypertension and uncontrolled BP among hypertensives, emphasis should be given to counsel patients on the importance of implementing lifestyle modifications.

Limitation of the study {#section15-2050312120946521}
-----------------------

The study has extensively addressed all relevant data regarding BP control and the determinants among treated hypertensive patients in HCs of Addis Ababa. However, there are certain limitations to mention. BP readings were taken from patients' medical records; hence, no information was available on how BP was measured. A cross-sectional study design was used, which does not allow a temporal relationship to be established. Since only public HCs of Addis Ababa were included, caution should be exercised in extrapolating the results to all HCs of Addis Ababa.

Conclusion {#section16-2050312120946521}
==========

BP control to target goal was suboptimal and achieved only in one-third of pharmacologically treated patients attending HCs of Addis Ababa. The frequently used antihypertensive drug classes were found to be thiazide diuretics, ACEIs, CCBs, alpha 2 agonist and β-blockers. The majority of the patients were on monotherapy. Alpha 2 agonist was the frequently used monotherapy while the combination of thiazide and ACEIs was the commonest combination therapy. Switching to another drug was the most common type of treatment modification. Age younger than 60 years, work status (being a government employee, a retired and in private business), and hypertension diagnosis of ⩾10 years were identified factors for poor BP control. While weekly BP measurement and tertiary level of education were important contributing factors that facilitate achieving target BP. This implies the need for closer monitoring of hypertensive patients attending the primary health care center. More emphasis should be given on identified determinants including age-based care, consider the patient level of awareness, and encourage patients to have more often BP monitoring practice, especially older patients with a prolonged history of hypertension. In addition, in light of new evidence showing the benefit of tighter BP control to reduce CVD morbidity and mortality associated with hypertension, the BP control practice in HCs of Addis Ababa should be frequently evaluated.
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